About 100 reports

  • TYPE 2 DIABETES DRUGS MARKET IN APAC
  • GLOBAL TYPE 2 DIABETES DRUGS MARKET
  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Type ## Diabetes: Disease Definition ##.

  • Type 2 Diabetes
  • Europe
  • France
  • World
  • Forecast
  • DEFRONZO RA, ET AL. (2014). NOVEL AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES. DIABETES SPECTRUM; 27: 100-112
  • T2DM Therapeutics, Global, All Pipeline Products, Discovery, April 2017
  • Type 2 Diabetes
  • Asia
  • World
  • Novo Nordisk Group
  • Sanofi S.A.
  • 2 Type 2 Diabetes (T2D): Executive Summary
  • T2D: KEY METRICS IN THE SEVEN MAJOR PHARMACEUTICAL MARKETS
  • Type 2 Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, 2016 and 2026
  • 2.1 RELATED REPORTS

Comparison of the prevalence of chronic kidney disease in Japanese patients with type ## and type ## diabetes.

  • Type 2 Diabetes
  • France
  • Germany
  • Spain
  • Forecast

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • France
  • Germany
  • Italy
  • Market Size

Type ## Diabetes: Disease Definition ##.

  • Type 2 Diabetes
  • Europe
  • France
  • Germany
  • Forecast

There are three types of diabetes: type ##, type ##, and gestational diabetes.

  • Type 2 Diabetes
  • Alcon, Inc.
  • IRIDEX Corporation
  • Synergetics USA, Inc.
  • Topcon Corporation

Japan Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Japan

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Japan
  • Demand

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • Europe
  • France
  • Germany
  • Market Size

Germany Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Germany

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Germany
  • Demand

UK Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) UK

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • United Kingdom
  • Demand

France Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) France

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • France
  • Demand

Italy Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Italy

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Italy
  • Demand

US Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) US

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Demand

Spain Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Spain

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Spain
  • Demand
  • Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Regional Hospital Holstebro, 2015* Stage of Development
  • NEPHROPATHY THERAPEUTICS, GLOBAL, TERMINATED CLINICAL TRIALS, 2015*
  • Type 2 Diabetes
  • World
  • Anthera Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Novartis AG
  • 4.2 RISK FACTORS AND COMORBIDITIES
  • 4.4 FORECAST METHODOLOGY

A TOTAL OF ##, ## PATIENTS WITH DIABETES (TYPE ## OR TYPE ##) WERE CONTINUOUSLY ENROLLED AT GHC FROM 1992-1995.

  • Type 2 Diabetes
  • Japan
  • FirstString Research, Inc.
  • Organogenesis, Inc.
  • Smith & Nephew Plc
  • TYPE 2 DIABETES GENE THERAPY
  • TYPE 2 DIABETES MONOCLONAL ANTIBODIES
  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Adjustable Gastric Band
  • Implantable Vagal Blocking Therapy
  • Type 2 Diabetes
  • United States
  • EnteroMedics Inc.
  • Novo Nordisk Group
  • VIVUS, Inc.
  • UPDATES
  • UPDATES
  • Type 2 Diabetes
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • SMALL MOLECULES TO AGONIZE GPR119 FOR TYPE 2 DIABETES - DRUG PROFILE
  • SMALL MOLECULE TO AGONIZE GPR119 FOR TYPE 2 DIABETES - DRUG PROFILE
  • Molecular Diagnostic
  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity
  • Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile
  • Insulin
  • Type 2 Diabetes
  • United States
  • World
  • DepYmed Inc.
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • Amgen Inc.
  • Synthetic Peptide to Agonize GLP-1 and GIP Receptors for Type 2 Diabetes
  • SYNTHETIC PEPTIDE 1 FOR TYPE 2 DIABETES AND OBESITY - DRUG PROFILE
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Small Molecules to Agonize TGR5 Receptor for Type 2 Diabetes - Drug Profile
  • Small Molecules to Agonize TGR-5 Receptor for Type 2 Diabetes and Obesity - Drug Profile
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • SMALL MOLECULES TO ACTIVATE GLUCOKINASE FOR TYPE 2 DIABETES - DRUG PROFILE
  • SMALL MOLECULES TO ACTIVATE GLUCOKINASE FOR TYPE 2 DIABETES - DRUG PROFILE
  • Diabetes
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • Type 2 Diabetes Mellitus, Global, Frequency and
  • Type 2 Diabetes Mellitus, Global, Percentage
  • Chronic Disease
  • Insulin
  • Pathology
  • Type 2 Diabetes
  • World
  • Type 2 Diabetes
  • Type 2 Diabetes
  • Biotechnology
  • Type 2 Diabetes
  • Company
  • Product Initiative
  • AstraZeneca PLC
  • SMALL MOLECULES TO ACTIVATE GLUCOKINASE FOR TYPE 2 DIABETES - DRUG PROFILE
  • SMALL MOLECULES TO ACTIVATE GLUCOKINASE FOR TYPE 2 DIABETES - DRUG PROFILE
  • Endocrine Disease
  • Type 2 Diabetes
  • China
  • Product Initiative
  • Hua Medicine